Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt 455.26
NAS:ABAX's Cash-to-Debt is ranked higher than
68% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. NAS:ABAX: 455.26 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ABAX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21  Med: 133.05 Max: No Debt
Current: 455.26
Equity-to-Asset 0.88
NAS:ABAX's Equity-to-Asset is ranked higher than
90% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NAS:ABAX: 0.88 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ABAX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.86 Max: 0.92
Current: 0.88
0.48
0.92
Interest Coverage 556.49
NAS:ABAX's Interest Coverage is ranked higher than
60% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. NAS:ABAX: 556.49 )
Ranked among companies with meaningful Interest Coverage only.
NAS:ABAX' s Interest Coverage Range Over the Past 10 Years
Min: 27.18  Med: N/A Max: No Debt
Current: 556.49
Piotroski F-Score: 5
Altman Z-Score: 21.58
Beneish M-Score: -2.35
WACC vs ROIC
9.72%
26.85%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 20.19
NAS:ABAX's Operating Margin % is ranked higher than
90% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. NAS:ABAX: 20.19 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ABAX' s Operating Margin % Range Over the Past 10 Years
Min: 12.42  Med: 16.77 Max: 26.55
Current: 20.19
12.42
26.55
Net Margin % 15.06
NAS:ABAX's Net Margin % is ranked higher than
90% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. NAS:ABAX: 15.06 )
Ranked among companies with meaningful Net Margin % only.
NAS:ABAX' s Net Margin % Range Over the Past 10 Years
Min: 8.36  Med: 11.53 Max: 15.18
Current: 15.06
8.36
15.18
ROE % 13.82
NAS:ABAX's ROE % is ranked higher than
76% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. NAS:ABAX: 13.82 )
Ranked among companies with meaningful ROE % only.
NAS:ABAX' s ROE % Range Over the Past 10 Years
Min: 7.67  Med: 11.53 Max: 16.35
Current: 13.82
7.67
16.35
ROA % 12.10
NAS:ABAX's ROA % is ranked higher than
89% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. NAS:ABAX: 12.10 )
Ranked among companies with meaningful ROA % only.
NAS:ABAX' s ROA % Range Over the Past 10 Years
Min: 6.77  Med: 10.01 Max: 14.32
Current: 12.1
6.77
14.32
ROC (Joel Greenblatt) % 54.64
NAS:ABAX's ROC (Joel Greenblatt) % is ranked higher than
83% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. NAS:ABAX: 54.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ABAX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 31.27  Med: 42.82 Max: 65.45
Current: 54.64
31.27
65.45
3-Year Revenue Growth Rate 5.80
NAS:ABAX's 3-Year Revenue Growth Rate is ranked higher than
56% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NAS:ABAX: 5.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ABAX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.5  Med: 15 Max: 166.8
Current: 5.8
4.5
166.8
3-Year EBITDA Growth Rate -1.50
NAS:ABAX's 3-Year EBITDA Growth Rate is ranked lower than
56% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. NAS:ABAX: -1.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ABAX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -33.6  Med: 13.3 Max: 222.4
Current: -1.5
-33.6
222.4
3-Year EPS without NRI Growth Rate -0.70
NAS:ABAX's 3-Year EPS without NRI Growth Rate is ranked higher than
50% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. NAS:ABAX: -0.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ABAX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -56.1  Med: 2.4 Max: 159.6
Current: -0.7
-56.1
159.6
GuruFocus has detected 1 Warning Sign with Abaxis Inc $NAS:ABAX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ABAX's 10-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ABAX Guru Trades in Q1 2016

Paul Tudor Jones 9,600 sh (New)
PRIMECAP Management 2,347,500 sh (+0.06%)
Steven Cohen Sold Out
Columbia Wanger Sold Out
Jim Simons 204,519 sh (-4.73%)
» More
Q2 2016

ABAX Guru Trades in Q2 2016

Joel Greenblatt 53,899 sh (New)
Jim Simons 226,871 sh (+10.93%)
Paul Tudor Jones Sold Out
PRIMECAP Management 2,333,000 sh (-0.62%)
» More
Q3 2016

ABAX Guru Trades in Q3 2016

PRIMECAP Management 2,323,000 sh (-0.43%)
Jim Simons 169,900 sh (-25.11%)
Joel Greenblatt 40,267 sh (-25.29%)
» More
Q4 2016

ABAX Guru Trades in Q4 2016

PRIMECAP Management 2,289,200 sh (-1.46%)
Jim Simons 130,500 sh (-23.19%)
Joel Greenblatt 4,801 sh (-88.08%)
» More
» Details

Insider Trades

Latest Guru Trades with ABAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 3826
Compare:NAS:GHDX, NAS:FMI, NAS:MYGN, NAS:KANG, NAS:MEDP, NAS:AXDX, NAS:VREX, NAS:ALOG, NAS:BEAT, NAS:QDEL, NAS:HSKA, NAS:NEO, NAS:NRCIA, OTCPK:EPLYF, NAS:VIVO, NYSE:ARA, NAS:PACB, NAS:NTRA, NYSE:NVTA, NAS:LNTH » details
Traded in other countries:AXS.Germany,
Headquarter Location:USA
Abaxis Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements.

Abaxis Inc is a California corporation and was incorporated in 1989. The Company is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. Its products and services include point-of-care diagnostic instruments and consumables used in the medical market and point-of-care diagnostic instruments and consumables used in the veterinary market. The Company manages its business in two reportable business segments, the medical market and the veterinary market, which are based on the diagnostic products sold and services provided by market and customer group. For products that it sells that are not specifically identified to any particular business segment, it categorizes the revenue as Other. The Company's products sold to the medical market are used by medical specialties requiring real time results to enable rapid clinical decisions in the area of human diagnostics. Its point-of-care products in the medical market are comprised of its Piccolo chemistry analyzers and consumable products. In the veterinary market, its VetScan products serves a customer group consisting of companion animal hospitals, animal clinics with mixed practices of small animals, birds and reptiles, equine and bovine practitioners, veterinary emergency clinics, veterinary referral hospitals, universities, government, pharmaceutical companies, biotechnology companies and private research laboratories. Its product and service offerings in the veterinary market include VetScan Point-of-Care Blood Chemistry Instruments, VetScan Profiles, Hematology Instruments and Consumables, VSpro Specialty Analyzers and Consumables, i-STAT Instruments and Consumables, Rapid Tests, and Abaxis Veterinary Reference Laboratories services. Its Other segment include sale of products using its patented Orbos Discrete Lyophilization Process (the Orbos process) to companies for other applications. The Orbos process involves flash-freezing a drop of liquid reagent to form a solid bead and then freeze-drying the bead to remove water. The Orbos beads are stable in dry form and dissolve rapidly in aqueous solutions. The dry reagents used in its reagent discs are produced using the Orbos process. This process allows the production of a precise amount of active chemical ingredient in the form of a soluble bead. The Company's competitors in the point-of-care human medical diagnostic market are Inverness Medical Switzerland GmbH, now known as Alere Switzerland GmbH ("Alere"), Alfa Wassermann S.P.A., Johnson & Johnson, Ortho-Clinical Diagnostics, Inc. and F. Hoffmann-La Roche Ltd. The Company's Piccolo products are in vitro diagnostic medical devices subject to regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act (FDCA).

Ratios

vs
industry
vs
history
PE Ratio 30.87
ABAX's PE Ratio is ranked lower than
51% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. ABAX: 30.87 )
Ranked among companies with meaningful PE Ratio only.
ABAX' s PE Ratio Range Over the Past 10 Years
Min: 20.75  Med: 42.4 Max: 75.53
Current: 30.87
20.75
75.53
Forward PE Ratio 34.84
ABAX's Forward PE Ratio is ranked lower than
80% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.79 vs. ABAX: 34.84 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 31.06
ABAX's PE Ratio without NRI is ranked lower than
52% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. ABAX: 31.06 )
Ranked among companies with meaningful PE Ratio without NRI only.
ABAX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 20.75  Med: 42.97 Max: 72.1
Current: 31.06
20.75
72.1
Price-to-Owner-Earnings 44.11
ABAX's Price-to-Owner-Earnings is ranked lower than
75% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. ABAX: 44.11 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ABAX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 16.03  Med: 51.28 Max: 352.63
Current: 44.11
16.03
352.63
PB Ratio 3.97
ABAX's PB Ratio is ranked lower than
57% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. ABAX: 3.97 )
Ranked among companies with meaningful PB Ratio only.
ABAX' s PB Ratio Range Over the Past 10 Years
Min: 2.19  Med: 4.55 Max: 8.07
Current: 3.97
2.19
8.07
PS Ratio 4.63
ABAX's PS Ratio is ranked lower than
61% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. ABAX: 4.63 )
Ranked among companies with meaningful PS Ratio only.
ABAX' s PS Ratio Range Over the Past 10 Years
Min: 2.48  Med: 4.97 Max: 8.56
Current: 4.63
2.48
8.56
Price-to-Free-Cash-Flow 39.98
ABAX's Price-to-Free-Cash-Flow is ranked lower than
72% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. ABAX: 39.98 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ABAX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 21.4  Med: 44.98 Max: 101.82
Current: 39.98
21.4
101.82
Price-to-Operating-Cash-Flow 29.90
ABAX's Price-to-Operating-Cash-Flow is ranked lower than
73% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. ABAX: 29.90 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ABAX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 17.14  Med: 33.15 Max: 79.01
Current: 29.9
17.14
79.01
EV-to-EBIT 19.34
ABAX's EV-to-EBIT is ranked higher than
57% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. ABAX: 19.34 )
Ranked among companies with meaningful EV-to-EBIT only.
ABAX' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.6  Med: 25.6 Max: 45.9
Current: 19.34
10.6
45.9
EV-to-EBITDA 16.84
ABAX's EV-to-EBITDA is ranked lower than
54% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. ABAX: 16.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.7  Med: 21.3 Max: 38.4
Current: 16.84
8.7
38.4
PEG Ratio 2.47
ABAX's PEG Ratio is ranked higher than
58% of the 43 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.96 vs. ABAX: 2.47 )
Ranked among companies with meaningful PEG Ratio only.
ABAX' s PEG Ratio Range Over the Past 10 Years
Min: 0.7  Med: 2.51 Max: 11.8
Current: 2.47
0.7
11.8
Shiller PE Ratio 49.87
ABAX's Shiller PE Ratio is ranked lower than
70% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.15 vs. ABAX: 49.87 )
Ranked among companies with meaningful Shiller PE Ratio only.
ABAX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 38.73  Med: 60.07 Max: 333.71
Current: 49.87
38.73
333.71
Current Ratio 7.74
ABAX's Current Ratio is ranked higher than
86% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. ABAX: 7.74 )
Ranked among companies with meaningful Current Ratio only.
ABAX' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 5.65 Max: 9.82
Current: 7.74
1.14
9.82
Quick Ratio 6.38
ABAX's Quick Ratio is ranked higher than
84% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. ABAX: 6.38 )
Ranked among companies with meaningful Quick Ratio only.
ABAX' s Quick Ratio Range Over the Past 10 Years
Min: 0.93  Med: 4.71 Max: 8.45
Current: 6.38
0.93
8.45
Days Inventory 132.38
ABAX's Days Inventory is ranked lower than
68% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. ABAX: 132.38 )
Ranked among companies with meaningful Days Inventory only.
ABAX' s Days Inventory Range Over the Past 10 Years
Min: 100.6  Med: 121.74 Max: 136.06
Current: 132.38
100.6
136.06
Days Sales Outstanding 56.93
ABAX's Days Sales Outstanding is ranked higher than
58% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. ABAX: 56.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.27  Med: 71.25 Max: 80.73
Current: 56.93
52.27
80.73
Days Payable 32.56
ABAX's Days Payable is ranked lower than
71% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. ABAX: 32.56 )
Ranked among companies with meaningful Days Payable only.
ABAX' s Days Payable Range Over the Past 10 Years
Min: 25.83  Med: 33.93 Max: 65.46
Current: 32.56
25.83
65.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.14
ABAX's Dividend Yield % is ranked higher than
56% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.97 vs. ABAX: 1.14 )
Ranked among companies with meaningful Dividend Yield % only.
ABAX' s Dividend Yield % Range Over the Past 10 Years
Min: 0.21  Med: 0.84 Max: 1.14
Current: 1.14
0.21
1.14
Dividend Payout Ratio 0.33
ABAX's Dividend Payout Ratio is ranked higher than
75% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.24 vs. ABAX: 0.33 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ABAX' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.32  Med: 0.38 Max: 0.44
Current: 0.33
0.32
0.44
Forward Dividend Yield % 1.14
ABAX's Forward Dividend Yield % is ranked higher than
51% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.15 vs. ABAX: 1.14 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.05
ABAX's 5-Year Yield-on-Cost % is ranked lower than
59% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. ABAX: 1.05 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ABAX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.21  Med: 0.84 Max: 1.11
Current: 1.05
0.21
1.11
3-Year Average Share Buyback Ratio -0.40
ABAX's 3-Year Average Share Buyback Ratio is ranked higher than
78% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. ABAX: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -32.5  Med: -4.65 Max: 0.4
Current: -0.4
-32.5
0.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 10.00
ABAX's Price-to-Net-Cash is ranked higher than
53% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.15 vs. ABAX: 10.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ABAX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 5.83  Med: 15.19 Max: 300
Current: 10
5.83
300
Price-to-Net-Current-Asset-Value 5.46
ABAX's Price-to-Net-Current-Asset-Value is ranked higher than
69% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. ABAX: 5.46 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ABAX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.22  Med: 7.21 Max: 41.25
Current: 5.46
2.22
41.25
Price-to-Tangible-Book 3.99
ABAX's Price-to-Tangible-Book is ranked higher than
60% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. ABAX: 3.99 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ABAX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.98  Med: 4.86 Max: 36.9
Current: 3.99
0.98
36.9
Price-to-Intrinsic-Value-Projected-FCF 2.03
ABAX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
51% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. ABAX: 2.03 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ABAX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.7  Med: 2.62 Max: 201
Current: 2.03
1.7
201
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.89
ABAX's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
65% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.84 vs. ABAX: 1.89 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.93
ABAX's Price-to-Median-PS-Value is ranked higher than
57% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. ABAX: 0.93 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ABAX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.31  Med: 1.03 Max: 25
Current: 0.93
0.31
25
Price-to-Peter-Lynch-Fair-Value 2.69
ABAX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
59% of the 27 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.57 vs. ABAX: 2.69 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ABAX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.52  Med: 2.43 Max: 11.04
Current: 2.69
0.52
11.04
Price-to-Graham-Number 2.35
ABAX's Price-to-Graham-Number is ranked higher than
62% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.97 vs. ABAX: 2.35 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ABAX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.46  Med: 3.03 Max: 13.38
Current: 2.35
1.46
13.38
Earnings Yield (Greenblatt) % 5.18
ABAX's Earnings Yield (Greenblatt) % is ranked higher than
74% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. ABAX: 5.18 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ABAX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.2  Med: 3.9 Max: 9.5
Current: 5.18
2.2
9.5
Forward Rate of Return (Yacktman) % 13.76
ABAX's Forward Rate of Return (Yacktman) % is ranked higher than
69% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. ABAX: 13.76 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ABAX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 6.9  Med: 16.8 Max: 44.4
Current: 13.76
6.9
44.4

More Statistics

Revenue (TTM) (Mil) $226.0
EPS (TTM) $ 1.48
Beta1.24
Short Percentage of Float18.32%
52-Week Range $41.89 - 55.95
Shares Outstanding (Mil)22.54

Analyst Estimate

Mar17 Mar18
Revenue (Mil $) 229 242
EPS ($) 1.35 1.41
EPS without NRI ($) 1.35 1.41
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ABAX

Headlines

Articles On GuruFocus.com
Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2017 and Declares Quarterly C Apr 27 2017 
Abaxis To Report Fourth Quarter And Fiscal Year 2017 Financial Results On Thursday, April 27, 2017 Apr 18 2017 
PRIMECAP Adds to Three Stakes in Portfolio Jul 07 2015 
Distribution: A Potentially Under-appreciated Moat Jun 08 2015 
ABAXIS Inc. (ABAX) COO Donald Peter Wood sells 6,460 Shares Mar 08 2011 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 35,000 Shares Dec 10 2010 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 96,000 Shares Dec 08 2010 
ABAXIS Inc. (ABAX) President,CEO & Board Chairman Clinton Severson sells 66,029 Shares Dec 07 2010 

More From Other Websites
Abaxis (ABAX) Beats Q4 Earnings Estimates, Revenues In Line Apr 28 2017
Edited Transcript of ABAX earnings conference call or presentation 27-Apr-17 8:15pm GMT Apr 28 2017
Abaxis tops 4Q profit forecasts Apr 27 2017
Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2017 and Declares Quarterly... Apr 27 2017
ABAXIS, Inc. – Value Analysis (NASDAQ:ABAX) : April 24, 2017 Apr 24 2017
ABAXIS, Inc. breached its 50 day moving average in a Bullish Manner : ABAX-US : April 21, 2017 Apr 21 2017
Abaxis To Report Fourth Quarter And Fiscal Year 2017 Financial Results On Thursday, April 27, 2017 Apr 18 2017
ABAXIS, Inc. : ABAX-US: Dividend Analysis : March 01st, 2017 (record date) : By the numbers : March... Mar 30 2017
New Strong Sell Stocks for March 1st Mar 01 2017
New Strong Sell Stocks for February 17th Feb 17 2017
ETFs with exposure to ABAXIS, Inc. : February 2, 2017 Feb 02 2017
ABAXIS, Inc. :ABAX-US: Earnings Analysis: Q3, 2017 By the Numbers : January 30, 2017 Jan 30 2017
Abaxis (ABAX) Q3 Bleak: Earnings In Line, Revenues Miss Jan 27 2017
Edited Transcript of ABAX earnings conference call or presentation 26-Jan-17 9:15pm GMT Jan 26 2017
Abaxis meets 3Q profit forecasts Jan 26 2017
Abaxis Reports Financial Performance for the Third Quarter of Fiscal 2017, Declares Quarterly Cash... Jan 26 2017
Medical Product Stocks' Earnings on Jan 26: ABMD, BCR, ABAX Jan 25 2017
ABAXIS, Inc. : ABAX-US: Dividend Analysis : December 01st, 2016 (record date) : By the numbers :... Jan 23 2017
Abaxis To Report Third Quarter Fiscal Year 2017 Financial Results On Thursday, January 26, 2017 Jan 19 2017
New Strong Sell Stocks for January 12th Jan 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)